Active secondary progressive multiple sclerosis
Clinical trials for Active secondary progressive multiple sclerosis explained in plain language.
Never miss a new study
Get alerted when new Active secondary progressive multiple sclerosis trials appear
Sign up with your email to follow new studies for Active secondary progressive multiple sclerosis, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New MS pill aims to slash relapses in major trial
Disease control OngoingThis phase 3 study tests an oral medication called IMU-838 against a placebo in about 1,100 adults with relapsing multiple sclerosis (MS). The goal is to see if the drug can reduce the number of relapses and new brain lesions over 72 weeks. Participants must be 18-55 years old wi…
Matched conditions: ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase 3 • Sponsor: Immunic AG • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New pill aims to stop MS relapses in its tracks
Disease control OngoingThis Phase 3 trial tests whether IMU-838 (vidofludimus calcium) can reduce relapses and brain lesions in adults with relapsing multiple sclerosis. Over 1,100 participants are randomly assigned to receive either the drug or a placebo for up to 72 weeks. The study is active but no …
Matched conditions: ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase 3 • Sponsor: Immunic AG • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo approach for MS: switching from natalizumab to cladribine
Disease control OngoingThis study looks at whether switching from natalizumab to cladribine tablets is safe and effective for people with relapsing forms of multiple sclerosis. About 40 adults aged 18-60 will take cladribine after stopping natalizumab. Researchers will track immune cell changes, relaps…
Matched conditions: ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase 4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Can Real-World data show how well multiple sclerosis patients stick with ofatumumab?
Knowledge-focused OngoingResearchers are studying how people with relapsing multiple sclerosis use ofatumumab in everyday practice in Germany and Japan. The study looks at insurance claims from about 5,000 adults to see how many stay on the treatment and how regularly they take it. It also tracks how oft…
Matched conditions: ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC